{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T04:07:20Z","timestamp":1762056440202,"version":"build-2065373602"},"reference-count":75,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2016M3A9B5942352","2021R1A2C301016611","2021R1F1A1063854","HI19C0758"],"award-info":[{"award-number":["2016M3A9B5942352","2021R1A2C301016611","2021R1F1A1063854","HI19C0758"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Ministry of Health and Welfare, Republic of Korea","doi-asserted-by":"publisher","award":["2016M3A9B5942352","2021R1A2C301016611","2021R1F1A1063854","HI19C0758"],"award-info":[{"award-number":["2016M3A9B5942352","2021R1A2C301016611","2021R1F1A1063854","HI19C0758"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cancer is a multifactorial and deadly disease. Despite major advancements in cancer therapy in the last two decades, cancer incidence is on the rise and disease prognosis still remains poor. Furthermore, molecular mechanisms of cancer invasiveness, metastasis, and drug resistance remain largely elusive. Targeted cancer therapy involving the silencing of specific cancer-enriched proteins by small interfering RNA (siRNA) offers a powerful tool. However, its application in clinic is limited by the short half-life of siRNA and warrants the development of efficient and stable siRNA delivery systems. Oncolytic adenovirus-mediated therapy offers an attractive alternative to the chemical drugs that often suffer from innate and acquired drug resistance. In continuation to our reports on the development of oncolytic adenovirus-mediated delivery of shRNA, we report here the replication-incompetent (dAd\/shErbB3) and replication-competent (oAd\/shErbB3) oncolytic adenovirus systems that caused efficient and persistent targeting of ErbB3. We demonstrate that the E1A coded by oAd\/shErbB, in contrast to dAd\/shErbB, caused downregulation of ErbB2 and ErbB3, yielding stronger downregulation of the ErbB3-oncogenic signaling axis in in vitro models of lung and breast cancer. These results were validated by in vivo antitumor efficacy of dAd\/shErbB3 and oAd\/shErbB3.<\/jats:p>","DOI":"10.3390\/ijms23137127","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T22:31:14Z","timestamp":1656369074000},"page":"7127","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["ErbB3-Targeting Oncolytic Adenovirus Causes Potent Tumor Suppression by Induction of Apoptosis in Cancer Cells"],"prefix":"10.3390","volume":"23","author":[{"given":"Bo-Kyeong","family":"Jung","sequence":"first","affiliation":[{"name":"Department of Bioengineering, College of Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea"},{"name":"GeneMedicine Co., Ltd., Seoul 04763, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Jun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, College of Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JinWoo","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, College of Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea"},{"name":"GeneMedicine Co., Ltd., Seoul 04763, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Gyu","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, College of Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A-Rum","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, College of Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea"},{"name":"Institute of Nano Science and Technology (INST), Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea"},{"name":"Hanyang Institute of Bioscience and Biotechnology (HY-IBB), Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9466-4531","authenticated-orcid":false,"given":"Chae-Ok","family":"Yun","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, College of Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea"},{"name":"GeneMedicine Co., Ltd., Seoul 04763, Korea"},{"name":"Institute of Nano Science and Technology (INST), Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea"},{"name":"Hanyang Institute of Bioscience and Biotechnology (HY-IBB), Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"11279","DOI":"10.1158\/0008-5472.CAN-06-2319","article-title":"Loss of Nrdp1 Enhances ErbB2\/ErbB3\u2013Dependent Breast Tumor Cell Growth","volume":"66","author":"Yen","year":"2006","journal-title":"Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1432-0436.2007.00238.x","article-title":"The epidermal growth factor receptor: From development to tumorigenesis","volume":"75","author":"Sibilia","year":"2007","journal-title":"Differentiation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1158\/0008-5472.CAN-04-1168","article-title":"A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells","volume":"64","author":"Wood","year":"2004","journal-title":"Cancer Res."},{"key":"ref_6","first-page":"7196","article-title":"The characterization of novel, dual ErbB-2\/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer","volume":"61","author":"Rusnak","year":"2001","journal-title":"Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1158\/1535-7163.MCT-15-0383","article-title":"Dual HER2\/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo","volume":"14","author":"Lopez","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_8","first-page":"25","article-title":"Cellular and molecular pharmacology of antiestrogen action and resistance","volume":"53","author":"Clarke","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"ref_9","first-page":"67","article-title":"Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations\u2014A review","volume":"4","author":"Stewart","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ncponc0509","article-title":"Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer","volume":"3","author":"Nahta","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.2011.38.6599","article-title":"Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer","volume":"30","author":"Weickhardt","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1158\/1535-7163.MCT-12-1208","article-title":"Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations","volume":"12","author":"Wheler","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s00432-012-1291-2","article-title":"Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer","volume":"138","author":"Wang","year":"2012","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/vco.12230","article-title":"Dual targeting of EGFR and ERBB2 pathways produces a synergistic effect on cancer cell proliferation and migration in vitro","volume":"15","author":"Gray","year":"2017","journal-title":"Vet. Comp. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Trusolino","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1158\/0008-5472.CAN-12-1611","article-title":"Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"R121","DOI":"10.1186\/bcr3067","article-title":"Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation","volume":"13","author":"Wang","year":"2011","journal-title":"Breast Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ctrv.2015.08.001","article-title":"Mechanisms of lapatinib resistance in HER2-driven breast cancer","volume":"41","author":"Raimondo","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"15411","DOI":"10.1007\/s13277-016-5467-2","article-title":"Lapatinib resistance in HER2+ cancers: Latest findings and new concepts on molecular mechanisms","volume":"37","author":"Shi","year":"2016","journal-title":"Tumour Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1111\/jcmm.12662","article-title":"Analysis of different HER-2 mutations in breast cancer progression and drug resistance","volume":"19","author":"Sun","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"8933","DOI":"10.1073\/pnas.1537685100","article-title":"The ErbB2\/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation","volume":"100","author":"Holbro","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","first-page":"E2836","article-title":"EGF and NRG induce phosphorylation of HER3\/ERBB3 by EGFR using distinct oligomeric mechanisms","volume":"114","author":"Agnew","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"16ra7","DOI":"10.1126\/scitranslmed.3000389","article-title":"Resiliency and vulnerability in the HER2-HER3 tumorigenic driver","volume":"2","author":"Amin","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"a020768","DOI":"10.1101\/cshperspect.a020768","article-title":"The EGFR family: Not so prototypical receptor tyrosine kinases","volume":"6","author":"Lemmon","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ydbio.2011.03.023","article-title":"EGFR signaling regulates cell proliferation, differentiation and morphogenesis during planarian regeneration and homeostasis","volume":"354","author":"Fraguas","year":"2011","journal-title":"Dev. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2217\/14796694.1.6.841","article-title":"Role of HER2\/HER3 co-receptor in breast carcinogenesis","volume":"1","author":"Way","year":"2005","journal-title":"Future Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/bcr792","article-title":"Essential function for ErbB3 in breast cancer proliferation","volume":"6","author":"Lloyd","year":"2004","journal-title":"Breast Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ijc.20867","article-title":"Anti-HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies","volume":"115","author":"Murgia","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/sj.onc.1208381","article-title":"Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549","volume":"24","author":"Sithanandam","year":"2005","journal-title":"Oncogene"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/sj.cgt.7700791","article-title":"Short interfering RNAs as a tool for cancer gene therapy","volume":"12","author":"Izquierdo","year":"2005","journal-title":"Cancer Gene Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nmat3765","article-title":"Delivery materials for siRNA therapeutics","volume":"12","author":"Kanasty","year":"2013","journal-title":"Nat. Mater."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1089\/104303403769211637","article-title":"Ad-mTERT-\u039419, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner","volume":"14","author":"Kim","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1517\/17425247.2014.874414","article-title":"Utilizing adenovirus vectors for gene delivery in cancer","volume":"11","author":"Kasala","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/sj.cgt.7700494","article-title":"Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy","volume":"9","author":"Kim","year":"2002","journal-title":"Cancer Gene Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/gt.2008.3","article-title":"Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: Effects on antiangiogenesis and tumor growth inhibition","volume":"15","author":"Yoo","year":"2008","journal-title":"Gene Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.18632\/oncotarget.3018","article-title":"Adenovirus expressing dual c-Met-specific shRNA exhibits potent antitumor effect through autophagic cell death accompanied by senescence-like phenotypes in glioblastoma cells","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/sj.mt.6300023","article-title":"VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth","volume":"15","author":"Yoo","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1126\/science.1096502","article-title":"High frequency of mutations of the PIK3CA gene in human cancers","volume":"304","author":"Samuels","year":"2004","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/ijc.22423","article-title":"Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells","volume":"120","author":"Liu","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0014-4827(02)00102-7","article-title":"Neuregulins: Functions, forms, and signaling strategies","volume":"284","author":"Falls","year":"2003","journal-title":"Exp. Cell Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3892\/or.2014.3330","article-title":"Neuregulin-1 induces cancer stem cell characteristics in breast cancer cell lines","volume":"32","author":"Jeong","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_42","first-page":"3394","article-title":"E1A Sensitizes HER2\/neu-overexpressing Ewing\u2019s Sarcoma Cells to Topoisomerase II-targeting Anticancer Drugs","volume":"61","author":"Zhou","year":"2001","journal-title":"Cancer Res."},{"key":"ref_43","first-page":"6712","article-title":"Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene","volume":"62","author":"Ueno","year":"2002","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/med.21735","article-title":"Recent developments in targeting genes and pathways by RNAi-based approaches in colorectal cancer","volume":"41","author":"Jebelli","year":"2021","journal-title":"Med. Res. Rev."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Wang, L., Li, F., Dang, L., Liang, C., Wang, C., He, B., Liu, J., Li, D., Wu, X., and Xu, X. (2016). In Vivo Delivery Systems for Therapeutic Genome Editing. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17050626"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-1-4939-8645-3_16","article-title":"Adeno-Associated Virus Delivery of Viral Serpins for Ocular Diseases: Design and Validation","volume":"1826","author":"Ildefonso","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Hromic-Jahjefendic, A., and Lundstrom, K. (2020). Viral Vector-Based Melanoma Gene Therapy. Biomedicines, 8.","DOI":"10.3390\/biomedicines8030060"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/sj.mt.6300110","article-title":"Replication-deficient adenovirus induces host topoisomerase I activity: Implications for adenovirus-mediated gene expression","volume":"15","author":"Zamir","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/cgt.2012.95","article-title":"Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers","volume":"20","author":"Choi","year":"2013","journal-title":"Cancer Gene Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/sj.gt.3302759","article-title":"Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect","volume":"13","author":"Choi","year":"2006","journal-title":"Gene Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.omto.2017.05.001","article-title":"A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model","volume":"5","author":"Kim","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s13277-014-2726-y","article-title":"Nrdp1 inhibits metastasis of colorectal cancer cells by EGFR signaling-dependent MMP7 modulation","volume":"36","author":"Jiang","year":"2015","journal-title":"Tumour Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"107526","DOI":"10.1016\/j.jmgm.2019.107526","article-title":"Systematic molecular profiling of inhibitor response to the clinical missense mutations of ErbB family kinases in human gastric cancer","volume":"96","author":"Ding","year":"2020","journal-title":"J. Mol. Graph. Model."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41388-019-1001-5","article-title":"ERBB3 mutations in cancer: Biological aspects, prevalence and therapeutics","volume":"39","author":"Kiavue","year":"2020","journal-title":"Oncogene"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e32271","DOI":"10.7554\/eLife.32271","article-title":"Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface","volume":"7","author":"Claus","year":"2018","journal-title":"Elife"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41388-020-01604-5","article-title":"A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance","volume":"40","author":"Conway","year":"2021","journal-title":"Oncogene"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/14737140.2020.1829485","article-title":"New insights into ErbB3 function and therapeutic targeting in cancer","volume":"20","author":"Hafeez","year":"2020","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2174\/1389557520999201214234421","article-title":"Resistance to Intervention: Paclitaxel in Breast Cancer","volume":"21","author":"Dan","year":"2021","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1245\/s10434-014-4061-3","article-title":"E1A-mediated inhibition of HSPA5 suppresses cell migration and invasion in triple-negative breast cancer","volume":"22","author":"Chen","year":"2015","journal-title":"Ann. Surg Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00005-014-0273-2","article-title":"The anti-tumor activity of E1A and its implications in cancer therapy","volume":"62","author":"Chang","year":"2014","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1007\/s11095-005-8178-8","article-title":"Sequence-specific suppression of mdr1a\/1b expression in mice via RNA interference","volume":"22","author":"Matsui","year":"2005","journal-title":"Pharm. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/cgt.2015.30","article-title":"Dual silencing of Bcl-2 and Survivin by HSV-1 vector shows better antitumor efficacy in higher PKR phosphorylation tumor cells in vitro and in vivo","volume":"22","author":"Chen","year":"2015","journal-title":"Cancer Gene Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.omto.2020.10.012","article-title":"Expression of Oncolytic Adenovirus-Encoded RNAi Molecules Is Most Effective in a pri-miRNA Precursor Format","volume":"19","author":"Brachtlova","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/jgm.1471","article-title":"Tumor suppression by apoptotic and anti-angiogenic effects of mortalin-targeting adeno-oncolytic virus","volume":"12","author":"Yoo","year":"2010","journal-title":"J. Gene Med."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Anesti, A.M., Simpson, G.R., Price, T., Pandha, H.S., and Coffin, R.S. (2010). Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-486"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"24832","DOI":"10.1074\/jbc.M114.565929","article-title":"Identification and functional characterization of nuclear mortalin in human carcinogenesis","volume":"289","author":"Ryu","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"42016","DOI":"10.1038\/srep42016","article-title":"Relevance of mortalin to cancer cell stemness and cancer therapy","volume":"7","author":"Yun","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.cgt.7700769","article-title":"ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis","volume":"12","author":"Yun","year":"2005","journal-title":"Cancer Gene Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/s41598-018-19300-6","article-title":"A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma","volume":"8","author":"Oh","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.biomaterials.2017.09.009","article-title":"A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response","volume":"147","author":"Jung","year":"2017","journal-title":"Biomaterials"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1089\/hum.2008.030","article-title":"Tumor-targeted radionuclide imaging and therapy based on human sodium iodide symporter gene driven by a modified telomerase reverse transcriptase promoter","volume":"19","author":"Kim","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jconrel.2015.10.015","article-title":"Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model","volume":"220","author":"Na","year":"2015","journal-title":"J. Control. Release"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/13\/7127\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:39:08Z","timestamp":1760139548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/13\/7127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":75,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["ijms23137127"],"URL":"https:\/\/doi.org\/10.3390\/ijms23137127","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2022,6,27]]}}}